43 results about "Desamethasone" patented technology

The invention relates to a dexamethasone sodium phosphate injection and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The preparation method comprises the following steps: 1, sequentially adding glycerol, edetate disodium and dexamethasone sodium phosphate into water for injection according to a weight ratio of (20-25): (0.08-0.12): (4-6), mixing and dissolving, and introducing nitrogen until the dissolved oxygen content is less than or equal to 1mg / L to obtain a liquid medicine 1; step 2, adding a pH regulator into the liquid medicine 1 to regulate the pH value to 7.0-8.5 to obtain liquid medicine 2; and step 3, filtering, filling and sealing the liquid medicine 2, and controlling the residual oxygen content to be less than or equal to 5% to obtain the dexamethasone sodium phosphate injection. Wherein the whole preparation process is protected by inert gas. According to the preparation method of the dexamethasone sodium phosphate injection provided by the invention, the prescription composition of an original drug does not need to be changed, and the prepared dexamethasone sodium phosphate injection can be stably stored at room temperature by adjusting a specific pH range, keeping filling of an inactive gas until the dissolved oxygen content is less than or equal to 1mg / L in the whole preparation process and controlling the residual oxygen content to be less than or equal to 5%.

The invention discloses oyster pallium hexapeptide with an effect of promoting osteogenesis as well as a preparation method and application of the oyster pallium hexapeptide. The amino acid sequence of the oyster pallium hexapeptide is Phe-Phe-Glu-Pro-Lys-Phe. Fresh oyster mantle is used as a raw material, pepsin and trypsin are used for hydrolysis and centrifugation to obtain supernate, then ultrafiltration is carried out to obtain filtrate with the molecular weight being 1000 Da or below, finally freeze drying is carried out, the sequence of oyster hydrolytic peptide is obtained through mass spectrum identification, and by means of a molecular docking technology and a database prediction simulation method, the oyster hydrolytic peptide is obtained. Oyster peptide with high osteogenesis promoting capacity is screened from a plurality of peptide sequences. The oyster hexapeptide obtained by the invention has the effects of improving osteoblast proliferation and differentiation capacity and improving dexamethasone-induced zebra fish bone loss, and can be used as a beneficial dietary supplement in related products for delaying bone loss.

The application discloses a construction method and application of an osteoarthritis cartilage organoid, and the method comprises the following steps: 1) mesenchymal stem cells are inoculated on a round bottom culture plate by a Micromass method, and are cultured in a chondrogenic induction culture medium containing dexamethasone, ascorbic acid and TGF-beta 3 for 10-18 days to form a transparent cartilage organoid; and 2) the transparent cartilage organoid is placed in an osteoarthritis induction culture medium containing dexamethasone, L-thyroxine, inflammatory factors (IL-1beta, IL-6 and TNF-alpha) and beta-glycerophosphate sodium for continuous culture for 5-10 days to obtain an osteoarthritis cartilage organoid; the model simultaneously presents multi-dimensional pathological characteristics such as matrix degeneration, hypertrophy, inflammation activation and vascularization trend, and can be used for osteoarthritis pathogenesis research, drug screening and cell treatment effect evaluation; the construction method is controllable and has good repeatability, and provides a reliable three-dimensional in-vitro model for osteoarthritis research.

This invention discloses a heterozygous sesquiterpene tricyclic epoxy compound derived from the strain *Arthrum oligosporum*, its preparation method, and its applications, belonging to the field of natural product chemistry. This invention provides a heterozygous sesquiterpene tricyclic epoxy compound derived from *Arthrum oligosporum* (… A.oligospora ) AOL_ s00210g57 Anthrobotrisin D, a novel heterozygous sesquiterpene tricyclic epoxy compound from a gene knockout strain, has been shown in vitro to possess excellent anti-inflammatory activity, significantly inhibiting lipopolysaccharide-induced inflammatory responses in mouse microglia. It exhibits a clear dose-dependent inhibitory trend at multiple levels, including NO release, protein and mRNA expression of inflammatory factors (TNF-α, IL-1β, IL-6), and iNOS protein and mRNA expression. Furthermore, at a concentration of 33 μM, its anti-inflammatory effect is comparable to that of the clinically proven positive drug dexamethasone, and in some aspects, it is even superior. This invention not only provides a new lead compound for the development of anti-inflammatory drugs but also opens up new directions for developing new drugs from the unique microbial resource of nematode-preying fungi.

This invention discloses a sodium alginate cross-linked matrix metalloproteinase-sensitive peptide-loaded dexamethasone sodium phosphate hydrogel and its preparation method. The dexamethasone-loaded hydrogel has good injectability. After injection, it is cleaved by MMPs at the site of inflammation in an inflammatory environment to release dexamethasone, exhibiting good sustained-release effect. It achieves targeted and long-acting treatment of inflammatory arthritis, osteoarthritis or other inflammatory diseases, and reduces the frequency of repeated intra-articular injections of glucocorticoids.

The invention discloses application of deaminotyrosine in improvement or prevention and treatment of muscular atrophy, and relates to the technical field of biological medicines. The invention finds that in the cellular level, DAT can effectively resist C2C12 myoblast senescence induced by etoposide; in a dexamethasone-induced C2C12 myotube atrophy model, DAT not only inhibits myotube diameter reduction from the form, but also down-regulates mRNA expression of key atrophy genes Atrogin-1 and MuRF-1 from the molecular level, and inhibits excessive activation of a ubiquitin-proteasome system; in-vivo animal experiments prove that DAT can reverse aging-related dyskinesia of rapidly-aged SAMP8 mice, and gait parameters of the rapidly-aged SAMP8 mice are all remarkably improved. According to the invention, a complete evidence chain from cells to the whole is constructed, and the DAT is proved to improve the senescent skeletal muscle atrophy through multiple ways of intervening cell senescence, antagonizing protein degradation, improving muscle microenvironment and the like, and shows important potential application value.

Provided are mixtures of dexamethasone-N-methacryloylglycylglycyl hydrazide (MA-Gly-Gly-NHN=Dex) monomers enriched in a desired diastereomer, and polymer compositions of same. Also provided are methods of treating inflammatory conditions such as arthritis that use the polymer compositions.

Corticosteroid compositions including a corticosteroid drug substance (e.g., fluocinolone, fluocinolone acetonide, dexamethasone, dexamethasone phosphate, dexamethasone sodium phosphate, triamcinolone, and triamcinolone acetonide) or a or a salt or derivative thereof and one or more irregular-shaped particulate fatty acid or keto-enol tautomer complexation agents admixed in a dispersal medium, having a release profile with one or more phases of drug release. These compositions are extended release corticosteroid compositions may release a clinically useful level of corticosteroid for more than 1 to 12 months within the body. Also described herein are methods of forming and methods of using these compositions.

A composition and method for treating COVID-19 includes a first component including approximately 10 mg of dexamethasone and a second component including approximately 48 mg to 80 mg of triamcinolone acetonide in combination with sodium chloride, benzyl alcohol, carboxymethylcellulose sodium, and polysorbate 80. When combined, the formulation provides dual-steroid therapy that reduces the need for tapering associated with high-dose dexamethasone, thereby minimizing adverse effects such as immunosuppression and secondary pneumonia. The composition is administered via injection and is effective for alleviating symptoms in patients with mild, moderate, or severe COVID-19 infections.

This invention specifically discloses a novel chalcone compound, its preparation method, pharmaceutical composition, and applications. Experimental results show that this compound exhibits significant anti-inflammatory activity in a lipopolysaccharide-stimulated RAW 264.7 cell model, significantly superior to the positive control drug dexamethasone; and in a free fatty acid-treated HepG2 cell model, it exhibits significant inhibition of lipid accumulation, significantly superior to the positive control drug obeticholic acid. It can be used to develop drugs for the treatment of non-alcoholic fatty liver disease, including but not limited to simple fatty liver, non-alcoholic steatohepatitis, and related cirrhosis.

The invention discloses an osteogenic differentiation induction medium based on pilose antler polypeptide and an osteogenic differentiation induction method, and belongs to the technical field of biology. The osteogenic differentiation induction culture medium based on the cornu cervi pantotrichum polypeptide contains a cornu cervi pantotrichum polypeptide solution, dexamethasone, L-ascorbic acid, beta-sodium glycerophosphate and a complete culture medium, the cornu cervi pantotrichum polypeptide provided by the invention can greatly improve the osteogenic differentiation effect of mesenchymal stem cells as an additive component of an osteogenic induction culture medium, and is superior to a commercial osteogenic induction culture medium in a certain scene; according to the osteogenic induction differentiation method disclosed by the invention, the defects in the prior art are improved, and the osteogenic differentiation effect of the mesenchymal stem cells can be improved by adopting the pilose antler polypeptide osteogenic differentiation induction culture medium.

The present application relates to dexamethasone acetate tablet friability detection technical field, specifically disclose a kind of dexamethasone acetate tablet friability detection device, including support mechanism, the turnover mechanism and electrostatic precipitation mechanism of support mechanism top being equipped, the turnover mechanism includes test box assembly, the electrostatic precipitation mechanism includes electrostatic generation assembly and the cathode assembly and anode assembly of electrostatic generation assembly side insertion;The electrostatic generation assembly includes support plate, the top of support plate is equipped with generator;In the present application, through generator to cathode assembly and anode assembly release positive and negative electrode static electricity, and then make test disc dust gather to the top of anode touch plate quickly, compared with artificial cleaning, cleaning is more thorough, and the tablet is dried and dehumidified, and drying is good, different work units are simultaneously used to realize different work contents, the cooperation between the two and mutual support, the detection of dexamethasone acetate tablet friability is realized, stability is high, and operation is simple.

This disclosure relates to methods for treating multiple myeloma. This disclosure relates to methods for treating newly diagnosed multiple myeloma in a subject in need, for example by subcutaneous administration of a pharmaceutical composition comprising an anti-CD38 antibody in combination with bortezomib, lenalidomide, and dexamethasone to the subject.

The application discloses a kind of photodynamic balloon catheter systems, comprising: tube body, with opposite proximal end and distal end;Balloon, the balloon is fixed in the distal end portion of the tube body;Optical fiber assembly is inserted in the tube body, and with the light-emitting site extending to adjacent the balloon;The surface of the balloon is loaded with auxiliary material and photosensitizer in the form of coating;The photosensitizer can activate collagen and elastin under the wavelength of light 400-460nm to make them crosslink;The auxiliary material includes active drug and sustained-release material wrapped the active drug, the active drug is at least one of paclitaxel, rapamycin, zotarolimus, tacrolimus, everolimus, temsirolimus, zanolimus, biolimus, docetaxel, protein-bound paclitaxel and protein-bound dexamethasone;By the photodynamic balloon catheter system of the application can improve the utilization rate of active drug in intravascular administration.

Isolated peptides capable of reducing the amount of dexamethasone-induced spleen and / or thymus weight loss in a mouse are disclosed as well as uses thereof. 20 24 27 84 77 16 D ec 2 02 4 A B S T R A C T 2 0 2 4 2 7 8 4 7 7 1 6 D e c 2 0 2 4

The invention relates to the field of medical application of biological hydrogel, in particular to dexamethasone loaded hydrogel delivered across tympanic membranes and a preparation method of the dexamethasone loaded hydrogel, the hydrogel takes gelatin Gel and dopamine modified hyaluronic acid HADA as base materials, a three-dimensional network structure is formed through enzymatic crosslinking of transglutaminase mTGase, dexamethasone sodium phosphate Dex is loaded, and the hydrogel can be used for preparing the dexamethasone loaded hydrogel. Furthermore, local trans-tympanic membrane middle ear drug delivery and release are realized; specifically, a solution A composed of Gel, HADA and Dex and a solution B composed of mTGase are evenly mixed according to the volume ratio of 4: 1 and dropwise added to the surface of the tympanic membrane through an external auditory canal, and finally Gel-HADA-Dex hydrogel is formed on the surface of the tympanic membrane. Local precise high-concentration drug delivery can be achieved, systemic drug toxicity is avoided, materials are safe, ear toxicity is avoided, meanwhile, adhesion performance is high, drug release is continuous, gradual self-degradation is achieved, manual taking out is not needed, and use convenience is remarkably improved.

CED-based methods, products and compositions for treating glioblastoma with anti-inflammatory therapeutics and chemotherapeutics without decreasing brain corticosterone compared to systemic delivery of dexamethasone, and not causing splenal atrophy and / or adrenal atrophy.

The invention discloses a directional preparation process of B crystal form dexamethasone. The process comprises the following steps: by taking 16-dehydropregnanone propionate as a starting material, sequentially performing catalytic dehydrogenation by using steroid 1, 4-dehydrogenase from bacillus subtilis, performing catalytic dehydrogenation by using potassium methyltrifluoroborate / copper acetate / 2, 4-dihydroxyprogesterone propionate as a starting material, and performing catalytic hydrogenation by using potassium methyltrifluoroborate / The preparation method comprises the following steps: preparing dexamethasone free alkali by key steps of stereoselective methylation of a 2, 2 '-bipyridine system, catalysis of 11 beta-hydroxylation by immobilized CYP11B1 monooxygenase, epoxidation of peroxybenzoic acid, ring opening of hydrogen fluoride-ethanol and the like, and finally directionally crystallizing in a system solution consisting of 0.5% malic acid and isopropanol-water in a volume ratio of 3: 1 to obtain the high-purity B crystal form dexamethasone.

The present application relates to the technical field of organic synthesis, and particularly provides an indole compound, a preparation method and application thereof. The chemical structural formula of the indole compound is shown as formula I. The provided indole compound can inhibit the growth of Jurkat leukemia cells in combination with dexamethasone at different concentrations, and the indole compound in combination with dexamethasone can activate the phosphorylation level of glucocorticoid, inhibit the PI3K / AKT and JAK2 / STAT3 signal pathways related to glucocorticoid resistance to overcome the drug resistance of glucocorticoid, and make the leukemia cells die.

The present application relates to the field of biotechnology, in particular, the application of E4BP4 in hematological diseases such as multiple myeloma. The present application proves that E4BP4 can be used as a potential biomarker and prognostic indicator for predicting the development of multiple myeloma, which is helpful for the treatment of multiple myeloma. Moreover, the E4BP4 protein can be used in the preparation of MM promoting reagents, which can be further used in the amplification of MM cells, the preparation of MM tumor metastasis models, the screening of MM treatment drugs and the like. After knocking down E4BP4, autophagy is induced and MM cell apoptosis is promoted, thereby enhancing the anti-myeloma effect of dexamethasone on MM. E4BP4 inhibitory drugs can be used as anti-myeloma drugs together with dexamethasone.

Implants comprising steroid dimers for use in improving vision and treating ocular disorders and conditions are provided. Said steroid dimers have the structure D1-L-D2 with D1 and D2 preferably being dexamethasone with the dexamethasone radicals linked by a hydrolyzable linker L. The implants provide for a controlled release of the dexamethasone with any treatment potentially involving the use of multiple implants intravitreally administered no less than 1 month, preferably no less than 3 months after intravitreally administration of the prior implant. The implants may also be used in conjunction with other therapeutic agents including anti-inflammatory or angiogenesis factors. These implants have utility in improving visual acuity, treating vision deterioration and treating ocular disorders and conditions, in particular by decreasing central subfield thickness.

The application discloses a kind of hexapeptide LE6 with anti-inflammatory activity and its preparation method and application, belong to small molecule peptide technical field.The amino acid sequence of the hexapeptide LE6 is LEPGFE, and can be prepared by solid-phase synthesis method and enzymatic hydrolysis method.This hexapeptide LE6 is identified from polysiphondryalis protease hydrolysate, has potential interaction with Keap1, and is found that low-dose (200mM) and high-dose (400mM) hexapeptide LR6 treatment can significantly reduce cell TNF-alpha, IL-1beta and IL-10 level in LPS-induced RAW264.7 cell test, wherein, the reducing effect of hexapeptide LR6 on TNF-alpha is superior to positive control dexamethasone, and hexapeptide LR6 can be used for preparing anti-inflammatory drug.

The invention relates to an external ointment for treating eczema and a preparation method thereof. Sinkiang lithospermum erythrorhizon, radix sophorae flavescentis and cortex phellodendri are used as monarch drugs. Sinkiang lithospermum erythrorhizon clears heat, cools blood, detoxifies and promotes eruption, radix sophorae flavescentis and cortex phellodendri clear heat, eliminate dampness, dispel wind and arrest itching, and directly act on the root of eczema damp-heat toxin. Salvia miltiorrhiza, radix rehmanniae, radix paeoniae rubra, cortex moutan and purslane are used as ministerial drugs. The radix rehmanniae, the radix paeoniae rubra and the cortex moutan are used for cooling blood and clearing heat, and the purslane is used for clearing away heat and toxic materials and assisting the monarch drug to enhance the effects of clearing heat and cooling blood, and dispersing blood stasis and relieving itching. Cynanchum paniculatum, radix saposhnikoviae, radix angelicae, platycodon grandiflorum, sanguisorba officinalis and cortex dictamni are used as adjuvant drugs. Radix cynanchi paniculati and divaricate saposhnikovia root dispel wind and arrest itching, radix angelicae dahuricae eliminates dampness and arrest itching, platycodon grandiflorum carries medicine and is transdermal, sanguisorba officinalis is used for cooling blood and astringing, cortex dictamni is used for clearing heat and eliminating dampness, and monarch and ministerial medicines are jointly assisted in A trace amount of dexamethasone is used for assisting rapid anti-inflammation, uncomfortable symptoms such as skin itch, papule and scabbing caused by eczema can be relieved, and instant pain of a patient can be rapidly relieved; skin barrier damage caused by eczema is improved, and normal physiological function recovery of skin is promoted.

The invention belongs to the technical field of biology, and particularly relates to a culture medium capable of differentiating and inducing amniotic fluid cells into myoblasts, a method and application. The culture medium contains 5% v / v serum, 0.1 [mu] M of dexamethasone, 50 [mu] M of hydrocortisone, 1 [mu] M of MCHIR99021 and 5-10 ng / mL of IGF-1, and a solvent is a low-sugar DMEM (Dulbecco Modified Eagle Medium). According to the invention, amniotic fluid cells are separated from amniotic fluid, and myoblasts can be obtained by using the culture medium to culture, differentiate and induce. According to the invention, efficient muscle differentiation and RYR1 gene overexpression of amniotic fluid cells are realized for the first time, and the gene has high fidelity on splicing variation after induced differentiation, so that a safe, rapid and low-cost solution is provided for prenatal clear gene diagnosis.

The invention discloses a preserving fluid for preserving pancreatic cancer tissues and application of the preserving fluid. The preserving fluid is prepared from mannitol, reduced glutathione, allopurinol, magnesium sulfate, gabexate mesylate, orlistat, pyruvic acid, Primocin, dexamethasone, heparin, bovine serum albumin, HEPES and the balance of an advance DMEM / F12 culture medium. The preserving fluid has a good effect in maintaining the pancreatic cancer tissue activity and inhibiting self-digestion and oxidative damage, is beneficial to maintaining the cell activity, and is beneficial to the preservation of pancreatic ductal adenocarcinoma in-vitro tissues and the construction of subsequent organoid.

The invention discloses a dexamethasone sodium phosphate freeze-dried composition suitable for ear drum administration and a preparation method of the dexamethasone sodium phosphate freeze-dried composition. The invention provides a freeze-dried powder injection preparation, the preparation is a dexamethasone drug freeze-dried powder injection, does not contain a freeze-drying supporting agent or an excipient or a support agent, the freeze-dried powder injection preparation contains a pharmaceutically acceptable auxiliary material glycerol, and the glycerol is added before the freeze-dried powder injection preparation is freeze-dried. The provided freeze-drying preparation does not contain a freeze-drying supporting agent or an excipient, the effect of improving the stability of the medicine can be achieved only by adding a small amount of glycerol before the preparation is freeze-dried, meanwhile, the osmotic pressure can be adjusted, so that the osmotic pressure is closer to physiological osmotic pressure during tympanic administration, and the action time of local administration is prolonged; and the safety and effectiveness of tympanic administration are improved.

The present invention relates to a co-crystal of dexamethasone (DEX) and a benzenediol, the co-crystal consisting of a 1:1 molar ratio of DEX and a benzenediol. The benzenediol can be catechol (CAT) or resorcinol (RES). The co-crystal of DEX and a benzenediol is formed by milling crystalline DEX with crystalline benzenediol combined in a 1:1 molar ratio. The milling can be performed at room temperature. The co-crystal can be heat annealed or exposed to moisture to enhance co-crystal formation. The DEX-CAT or DEX-RES co-crystal can be included in a medicament for the treatment of allergy, asthma, rhinitis, cancer, diabetes, anemia, ulcer, and viral infection. The DEX-benzenediol co-crystal can be screened to provide particles in the range of 10 to 45 pm, which can be used for intranasal administration, with improved dissolution properties.

Title: Injectable Formulations of Dexamethasone The present invention relates to the injectable formulations of dexamethasone. In particular the invention relates to the stable, injectable formulation of dexamethasone that are ready to use diluted form. The invention further relates to process to prepare injectable formulations of dexamethasone and method of use thereof.

The invention discloses a supramolecular polypeptide-drug coupled prodrug nano material for treating multiple myeloma as well as a preparation method and application of the supramolecular polypeptide-drug coupled prodrug nano material. According to the nano material, hyaluronic acid modified by beta-cyclodextrin is taken as a skeleton, and a melphalan-dexamethasone double-drug coupling compound coupled with an adamantane modified GFLG short peptide connexon is loaded through a supramolecular host-guest effect. The nano material has good stability and drug entrapment capacity under physiological conditions, and can realize quick-response drug release under the condition of simulating an enzymatic environment in myeloma cells. The nano material can realize efficient cellular uptake and specific drug activated release, so that proliferation of multiple myeloma cells is inhibited, and a new strategy for delivery of the multiple myeloma nano drug with a synergistic treatment effect is provided.